Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 27, 2026
Antares agreement establishes a TRISO production framework
NYSE: $BWXTNaval propulsion and nuclear industrial infrastructure
BWXT Stock Hub: BWX Technologies News, Naval Nuclear and Commercial Growth
BWXT combines an established naval nuclear business with commercial power equipment, services and advanced fuel opportunities. June backlog was approximately $8.4 billion, including unfunded government work, while Q2 revenue was $901.6 million. PCG joined the portfolio in July, and the announced medical transaction could change its future scope. Third-quarter results are scheduled for November 2 after the U.S. close.
Full research report · PDF
BWX Technologies, Inc. research · November 1, 2026
18 pages covering the business, financial position, catalysts, risks, scenarios and sources. A dated snapshot for personal use; redistribution prohibited.
Next catalyst
2026-11-02 · Third-quarter results and conference call
Company-confirmed release after the U.S. close; call at 5:00 p.m. Eastern. Announcement and terms
BWXT stock at a glance
Reference equity value
11.97
USD billion · 2026-10-30 · Calculated using 91,621,980 common shares reported at July 31. Market and share-count dates differ; future dilution is excluded.
SourceCash and equivalents
608.2
USD million · 2026-06-30 · Precedes the July 1 PCG acquisition. Restricted balances are separate.
SourceDebt carrying amount
2,019.9
USD million · 2026-06-30 · Balance-sheet carrying value differs from the aggregate principal of the note issues.
SourceNet income attributable to BWXT
89.0
USD million · Q2 2026 · After the noncontrolling-interest allocation; consolidated net income was $89.098 million.
SourceBacklog
8,398.1
USD million · 2026-06-30 · Includes $2,256.4 million of unfunded U.S. government backlog; excludes unexercised options and unconsolidated joint ventures.
SourceWhere BWX Technologies, Inc. stands now
Naval fuel and components support the operating base, while commercial growth includes acquisitions and a wider nuclear service offering. The Antares agreement creates a fuel-production framework; Janus and the Canadian BANR proposal remain at development stages with further agreements and approvals required.
June cash was $608.2 million before the PCG acquisition. Management’s September presentation separately adjusted that balance to approximately $400 million after the transaction. The longer-term targets depend on contract execution, commercial growth, margin improvements and disciplined capital allocation.
The main risk is committing resources ahead of profitable execution. Contract-cost changes, government funding, customer schedules and development or acquisition delays can weaken cash returns even when the long-term nuclear market remains attractive.
The constructive case
Reliable naval execution, useful contributions from commercial acquisitions and repeat fuel work support margins and cash. Disciplined investment turns a larger nuclear opportunity into sustainable earnings per share.
The cautious case
Less favorable contract costs, delayed customer decisions or slower integration increase the resources needed for growth. Weaker cash conversion and financing costs reduce the return retained by existing common shares.
Latest BWX Technologies, Inc. news
Oct 27, 2026
Antares agreement establishes a TRISO production framework
The multiyear agreement includes terms for an initial allocation of one metric ton of uranium. Future task orders will define quantities, delivery schedules and technical requirements as the reactor program advances.
Oct 22, 2026
BWXT clarifies the status of Polish discussions
The company said no investment decision had been made concerning potential Polish microreactor and SMR opportunities. Any investment would depend on firm orders and the extent of the opportunity.
Oct 5, 2026
BANR selected for a proposed Canadian transportable plant
Prodigy and two First Nations selected BANR for the Belledune proposal, targeting service in the early 2030s. The parties are working toward definitive arrangements covering development, licensing, financing and deployment.
Oct 1, 2026
Naval fuel contract schedules work through August 2027
Nuclear Fuel Services will manufacture and deliver naval reactor fuel under an approximately $189 million contract. Completion is scheduled for August 2027.
Oct 1, 2026
Third-quarter earnings scheduled for November 2
BWXT will release results after the U.S. market closes and host a conference call at 5:00 p.m. Eastern.
Sep 29, 2026
Investor day sets out the longer-term financial framework
Management reaffirmed the 2026 outlook and described 2030 targets of $5.5 billion–$6.0 billion revenue, $1.1 billion–$1.2 billion adjusted EBITDA and $525 million–$575 million free cash flow. These are forward-looking company targets.
BWXT stock catalysts
- 2026-11-02 · Third-quarter results and conference callCompany-confirmed release after the U.S. close; call at 5:00 p.m. Eastern.
- Late 2026 or early 2027 · Expected medical transaction closingCompany expectation in the September presentation; completion remains subject to conditions and approvals.
- 2027-08 · Naval fuel contract completionScheduled completion month announced for the approximately $189 million award.
- Future task orders; dates unannounced · Antares TRISO production and deliveryA multiyear framework is signed; task orders will define quantities, schedules and requirements.
- Phased program; dates unannounced · Janus site and development milestonesTechnology selected, with site work, regulatory processes and fuel fabrication among the initial activities.
- Early 2030s · Canadian transportable plant service targetProject development target; definitive arrangements, licensing, financing and construction remain ahead.
Four stages of the current opportunity
| Activity | Current position | Economic test |
|---|---|---|
| Naval components and fuel | Established operations with new awards | Safe delivery, contract margins and payment |
| Commercial power and PCG | Operating business; acquisition closed July 1 | Integration, utilization and returns on acquired capital |
| Antares TRISO | Multiyear framework signed | Task orders, qualified production and receipts |
| BANR projects | Technology selections and development programs | Agreements, approvals, financing and deployment |
The stages have different capital needs and revenue timetables.
June cash flow and the following acquisition
| Measure | US$ million | Basis |
|---|---|---|
| Operating cash inflow | 249.003 | First half 2026 |
| PP&E purchases | 83.937 | First half 2026 |
| Operating cash less PP&E | 165.066 | First half arithmetic, before PCG acquisition |
| Cash and equivalents | 608.203 | June 30 actual balance |
PCG closed July 1. September’s approximately $400 million cash presentation adjusts June for that acquisition and is a separate pro forma reference.
Merlintrader Health Score · $BWXT
3.55out of 5
Assessed November 1, 2026. An editorial assessment of financial and operating resilience over twelve to eighteen months; no price target or recommendation is implied.
Red flags
- Backlog includes unfunded government work and spans several years.
- Unexercised options and unconsolidated joint-venture contract values are outside reported backlog.
- Over-time contract estimates can materially affect the period’s revenue and profit.
- The June cash balance precedes the July PCG acquisition and any future medical-sale proceeds.
- The medical transaction remains subject to closing conditions; its upper valuation is separate from cash received.
- Advanced reactor selections require subsequent development, licensing, financing and operating work.
- Convertible debt, incentive awards and financing choices affect the residual value per share.
- Nuclear safety, environmental responsibilities, workforce and specialized supply chains carry long-lived obligations.
BWXT Stock FAQ: BWX Technologies, Inc. Questions Answered
Does BWXT already have an operating nuclear business?
Yes. The company supplies naval nuclear components and fuel, commercial power equipment and services, and specialized government work. Q2 revenue was $901.6 million. Advanced reactor development adds opportunities alongside that established earnings base.
Is all the backlog already funded?
June backlog included approximately $2.256 billion of unfunded U.S. government work. Revenue and cash follow performance, appropriations and payment terms. The total excludes unexercised options and unconsolidated joint-venture contract values.
Has the medical sale already generated $800 million of cash?
The announced transaction is valued at up to $800 million and remains subject to closing conditions. September’s presentation expected completion in late 2026 or early 2027 and described an approximately 20% retained stake. The financial result follows the actual closing terms and timing.
Are the new reactor announcements operating plants?
Janus and the Canadian proposal have development and authorization stages ahead. The Antares fuel agreement establishes a commercial framework, with future task orders setting quantities and deliveries. Their current status differs from mature operating contracts.
When are the next earnings due?
BWXT scheduled Q3 results for November 2, after the U.S. market closes, followed by a 5:00 p.m. Eastern call. The complete financial baseline here covers June 30, with later announcements identified separately.
Primary sources and market references
- June financial statements
- results schedule
- Annual business description
- naval contract announcement
- October fuel contract
- Quarterly operating review
- September investor presentation
- Medical sale announcement
- BANR Canadian project
- Army Janus selection
- TRISO business description
- Antares agreement
- Proxy ownership disclosures
- Fitch announcement
- October Poland statement
- market reference
- company's investor pages
Disclaimer. Published by Merlintrader for educational and informational purposes only. This content does not constitute investment advice or a recommendation to buy, sell or hold securities. Verify figures against the dated primary disclosures. Investors can lose part or all of their capital.
Nuclear manufacturing and development involve technical, quality, safety, security, environmental, government-funding, contract and customer risks. Acquisitions, licensing, financing, contingent milestones and potential dilution affect the return retained by common shareholders.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information: disclaimer and terms of use and privacy.
